Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Gross Profit | -1.5M | 11.1% |
Cost of Revenue | 1.5M | 11.1% |
Operating expense | 3.5M | 4.7% |
Net Income | -3.5M | 7.1% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 2.6M | 17.2% |
Total Liabilities | 5.4M | 24% |
Shares Outstanding | 2.8M | 142.3% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | -1.6M | 78.7% |
Cash from financing | 1.6M | 263.1% |
EPS
Financial Highlights for Virpax Pharmaceuticals in Q2 '24
Gross Profit stood at -1.5M, marking a 11.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 1.5M, a -11.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 3.5M, showing a 4.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -3.5M, showing a -7.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Virpax Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.